Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Alzheimer's disease (AD) is characterized by enhanced beta-amyloid peptide (betaA) deposition along with glial activation in senile plaques, selective neuronal loss, and cognitive deficits. Cannabinoids are neuroprotective agents against excitotoxicity in vitro and acute brain damage in vivo. This background prompted us to study the localization, expression, and function of cannabinoid receptors in AD and the possible protective role of cannabinoids after betaA treatment, both in vivo and in vitro. Here, we show that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microglial activation. In pharmacological experiments, we found that G-protein coupling and CB1 receptor protein expression are markedly decreased in AD brains. Additionally, in AD brains, protein nitration is increased, and, more specifically, CB1 and CB2 proteins show enhanced nitration. Intracerebroventricular administration of the synthetic cannabinoid WIN55,212-2 to rats prevent betaA-induced microglial activation, cognitive impairment, and loss of neuronal markers. Cannabinoids (HU-210, WIN55,212-2, and JWH-133) block betaA-induced activation of cultured microglial cells, as judged by mitochondrial activity, cell morphology, and tumor necrosis factor-alpha release; these effects are independent of the antioxidant action of cannabinoid compounds and are also exerted by a CB2-selective agonist. Moreover, cannabinoids abrogate microglia-mediated neurotoxicity after betaA addition to rat cortical cocultures. Our results indicate that cannabinoid receptors are important in the pathology of AD and that cannabinoids succeed in preventing the neurodegenerative process occurring in the disease.
Ramírez
Belén G
BG
Neurodegeneration Group, Cajal Institute, Consejo Superior de Investigaciones Científicas, 28002 Madrid, Spain.
Blázquez
Cristina
C
Gómez del Pulgar
Teresa
T
Guzmán
Manuel
M
de Ceballos
María L
ML
D000368:Aged; D000544:Alzheimer Disease / Q000503:physiopathology / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D048588:Benzoxazines; D002186:Cannabinoids / Q000008:administration & dosage / Q000494:pharmacology*; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D018920:Coculture Techniques; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D009281:Naphthalenes / Q000008:administration & dosage / Q000494:pharmacology*; D009410:Nerve Degeneration / Q000517:prevention & control; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D009569:Nitric Oxide / Q000378:metabolism; D010446:Peptide Fragments / Q000633:toxicity; D058225:Plaque, Amyloid / Q000187:drug effects* / Q000378:metabolism; D011499:Protein Processing, Post-Translational / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists* / Q000502:physiology; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016229:Amyloid beta-Peptides; D048588:Benzoxazines; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D009025:Morpholines; D009281:Naphthalenes; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D014409:Tumor Necrosis Factor-alpha; C074636:amyloid beta-protein (25-35); D009569:Nitric Oxide; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D013759:Dronabinol; C062018:HU 211; C432747:1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
J Pharmacol Exp Ther. 1999 Mar;288(3):1357-66
10027878
J Med Chem. 1999 Feb 25;42(4):769-76
10052983
J Neurosci. 1999 Apr 15;19(8):2987-95
10191316
Neuroscience. 1999;92(4):1177-91
10426477
J Neuropathol Exp Neurol. 1999 Nov;58(11):1163-9
10560659
Glia. 2000 Jan 1;29(1):58-69
10594923
Neurosci Lett. 2000 Jan 7;278(1-2):69-72
10643803
Bioorg Med Chem. 1999 Dec;7(12):2905-14
10658595
Ann Neurol. 2000 Apr;47(4):524-7
10762167
Neuroscience. 2000;97(3):505-19
10828533
Neurobiol Aging. 2000 May-Jun;21(3):383-421
10858586
Nat Med. 2000 Aug;6(8):916-9
10932230
Neurobiol Dis. 2000 Aug;7(4):429-47
10964613
J Neurosci. 2000 Oct 15;20(20):7587-94
11027218
Eur J Neurosci. 2001 Apr;13(8):1529-36
11328347
Nat Med. 2001 May;7(5):612-8
11329064
Mol Pharmacol. 2001 Jul;60(1):155-63
11408610
Neuroscience. 2001;104(3):609-13
11440793
Cancer Res. 2001 Aug 1;61(15):5784-9
11479216
J Neurosci. 2001 Sep 1;21(17):6475-9
11517236
Nature. 2001 Oct 4;413(6855):527-31
11586361
J Neurosci. 2002 Feb 1;22(3):782-90
11826108
Brain Res. 2002 Feb 22;928(1-2):76-84
11844474
Neuroscience. 2002;110(1):49-58
11882372
J Neurosci. 2002 Mar 15;22(6):2246-54
11896164
J Neurochem. 2002 Feb;80(3):448-56
11905991
J Neurosci. 2002 May 1;22(9):3484-92
11978825
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135
Neurosci Lett. 2002 Jun 14;325(3):199-202
12044655
J Biol Chem. 2002 Sep 27;277(39):36527-33
12133838
Neurosci Lett. 2002 Oct 31;332(2):127-30
12384227
Nat Neurosci. 2002 Nov;5 Suppl:1058-61
12403986
J Neurosci. 2002 Nov 15;22(22):9742-53
12427829
J Neurosci. 2002 Nov 15;22(22):9771-5
12427832
Glia. 2003 Jan 15;41(2):161-8
12509806
J Neurosci. 2003 Feb 15;23(4):1398-405
12598628
Science. 2003 Oct 3;302(5642):84-8
14526074
Nat Rev Neurosci. 2003 Nov;4(11):873-84
14595399
J Neurosci. 2003 Dec 3;23(35):11136-41
14657172
Neurosci Lett. 1992 Dec 7;147(2):179-81
1491804
Neuropharmacology. 2004 Apr;46(5):716-26
14996549
Neurobiol Dis. 2004 Apr;15(3):580-9
15056466
Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
2308954
Am J Pathol. 1988 Jul;132(1):86-101
2456021
Neurosci Lett. 1987 Aug 18;79(1-2):195-200
3670729
J Cell Biol. 1980 Jun;85(3):890-902
6248568
Mol Pharmacol. 1995 Sep;48(3):443-50
7565624
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9328-32
7568127
Nature. 1995 Apr 13;374(6523):647-50
7715705
J Biol Chem. 1995 Jun 9;270(23):13973-80
7775459
Neuroscience. 1994 Dec;63(3):637-52
7898667
Cell. 1994 Dec 2;79(5):755-65
8001115
FEBS Lett. 1994 Aug 22;350(2-3):240-4
8070571
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3984-9
8633002
J Neurosci. 1996 Sep 15;16(18):5795-811
8795633
J Exp Med. 1996 Oct 1;184(4):1425-33
8879214
Eur J Pharmacol. 1997 Jan 14;319(1):1-4
9030890
J Neurosci. 1997 Apr 15;17(8):2653-7
9092586
J Pharmacol Exp Ther. 1997 Sep;282(3):1632-42
9316881
Am J Pathol. 1998 Jan;152(1):307-17
9422548
J Pharmacol Exp Ther. 1998 Feb;284(2):644-50
9454810
Neuroscience. 1997 Mar;77(2):299-318
9472392
J Neurosci. 1998 Mar 15;18(6):2161-73
9482801
Neuroscience. 1998 Jun;84(4):1075-83
9578396
Neurobiol Aging. 1998 May-Jun;19(3):201-4
9661994
Br J Pharmacol. 1998 Jun;124(4):619-22
9690851
Mol Pharmacol. 1998 Sep;54(3):459-62
9730904
FEBS Lett. 1998 Sep 25;436(1):6-10
9771884
Microsc Res Tech. 1998 Oct 1;43(1):75-88
9829462